Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies (Q77653346)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

Hideaki Kodama

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Masanori Suzuki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Yu Katayose

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Masao Shinoda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Naoki Sakurai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Shin-ichi Takemura

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Hiroshi Yoshida

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Hisaaki Saeki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Ryutaro Asano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Masahiko Ichiyama

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Kohzoh Imai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Yuji Hinoda

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Seiki Matsuno

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Toshio Kudo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 April 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

99-106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

Preliminary trial of specific targeting therapy against malignant glioma

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Primary structure of the variable regions of a monoclonal antibody MUSE11 recognizing the tandem repeat domain of a mucin core protein, MUC1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

An in-vitro model for tumor immunotherapy with antibody heteroconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

The role of the CD28 receptor during T cell responses to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Tumor Therapy by Immune Recruitment with Bispecific Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

The transmembrane region of CD2-associated signal-transducing proteins is crucial for the outcome of CD2-mediated T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

The roles of Fas and perforin in LAK T-cell/bispecific antibody-mediated killing of the murine B-lymphoma cells, BCL1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

Construction of a diabody (small recombinant bispecific antibody) using a refolding system

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2801%2900343-1

7 January 2021

10.1016/S0165-2478(01)00343-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852114%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference